Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRCT2017030120258N35Phase 3Completed
Phase 3 trial of melatonin in multiple sclerosis (MS), sponsored by Arak University of Medical Sciences. Primary endpoint: Fatigue severity. Started Jun 2015; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on IRCT2017030120258N35.